Novel therapeutic targets in chordoma

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 11, 2012, Pages 1139-1143

  Bydon, Mohamad ^a   Papadimitriou, Kyriakos ^a   Witham, Timothy ^a   Wolinsky, Jean Paul ^a   Bydon, Ali ^a   Sciubba, Daniel ^a   Gokaslan, Ziya ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Brachyury; CDKN2A; Chordoma; Imatinib; JHC7 chordoma cell line; Met; PTEN

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BRACHYURY; CAMPTOTHECIN DERIVATIVE; CETUXIMAB; CISPLATIN; DASATINIB; EVEROLIMUS; GEFITINIB; IMATINIB; KERATIN; LAPATINIB; MICRORNA; NILOTINIB; PANOBINOSTAT; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CDKN2A GENE; CELL PROLIFERATION; CHORDOMA; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG EFFICACY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; PATHOGENESIS; PTEN GENE; REVIEW; SACRUM; SKULL BASE; SPINE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHORDOMA; FETAL PROTEINS; GENES, P16; HUMANS; MICRORNAS; PTEN PHOSPHOHYDROLASE; T-BOX DOMAIN PROTEINS;

EID: 84867491814     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.714772     Document Type: Review

References (38)

1. Healey JH, Lane JM. Chordoma: A critical review of diagnosis and treatment. Orthop Clin North Am 1989;20(3):417-26
2. Walcott BP, Nahed BV, Mohyeldin A, et al. Chordoma: Current concepts, management, and future directions. Lancet Oncol 2012;13(2):e69-73
3. McPherson CM, Suki D, McCutcheon IE, et al. Metastatic disease from spinal chordoma: A 10-year experience. J Neurosurg Spine 2006;5(4):277-80
4. Hsu W, Mohyeldin A, Shah SR, et al. Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target. J Neurosurg 2011;115(4):760-9
5. McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001;12(1):1-11
6. DeLaney TF, Liebsch NJ, Pedlow FX, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 2009;74(3):732-9
7. Fourney DR, Rhines LD, Hentschel SJ, et al. En bloc resection of primary sacral tumors: Classification of surgical approaches and outcome. J Neurosurg Spine 2005;3(2):111-22
8. Hsieh PC, Xu R, Sciubba DM, et al. Long-term clinical outcomes following en bloc resections for sacral chordomas and chondrosarcomas: A series of twenty consecutive patients. Spine 2009;34(20):2233-9
9. Boriani S, Bandiera S, Biagini R, et al. Chordoma of the mobile spine: fifty years of experience. Spine 2006;31(4):493-503
10. Hsieh PC, Gallia GL, Sciubba DM, et al. En bloc excisions of chordomas in the cervical spine: Review of five consecutive cases with more than 4-year follow-up. Spine 2011;36(24):E1581-7
11. Oakley GJ, Fuhrer K, Seethala RR. Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: A tissue microarray-based comparative analysis. Mod Pathol 2008;21(12):1461-9
12. Siu IM, Salmasi V, Orr BA, et al. Establishment and characterization of a primary human chordoma xenograft model. J Neurosurg 2012;116(4):801-9
13. Yang XR, Ng D, Alcorta DA, et al. T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet 2009;41(11):1176-8
14. Presneau N, Shalaby A, Ye H, et al. Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: A genetic and functional-based study. J Pathol 2011;223(3):327-35
15. Fernando RI, Litzinger M, Trono P, et al. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest 2010;120(2):533-44
16. Roselli M, Fernando RI, Guadagni F, et al. Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: An opportunity for novel interventions against lung cancer. Clin Cancer Res 2012
17. Duan Z, Choy E, Nielsen GP, et al. Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression. J Orthop Res 2010;28(6):746-52
18. Medina PP, Slack FJ. microRNAs and cancer: An overview. Cell Cycle 2008;7(16):2485-92
19. Phillip CJ, Stellrecht CM, Nimmanapalli R, Gandhi V. Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol 2009;63(4):587-97
20. Naka T, Iwamoto Y, Shinohara N, et al. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors. Mod Pathol 1997;10(8):832-8
21. Brandal P, Bjerkehagen B, Danielsen H, Heim S. Chromosome 7 abnormalities are common in chordomas. Cancer Genet Cytogenet 2005;160(1):15-21
22. Scheil S, Bruderlein S, Liehr T, et al. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 2001;32(3):203-11
23. Le LP, Nielsen GP, Rosenberg AE, et al. Recurrent chromosomal copy number alterations in sporadic chordomas. PLoS One 2011;6(5):e18846
24. Han S, Polizzano C, Nielsen GP, et al. Aberrant hyperactivation of akt and mammalian target of rapamycin complex 1 signaling in sporadic chordomas. Clin Cancer Res 2009;15(6):1940-6
25. Liu X, Nielsen GP, Rosenberg AE, et al. Establishment and characterization of a novel chordoma cell line: CH22. J Orthop Res 2012
26. Yang C, Hornicek FJ, Wood KB, et al. Characterization and analysis of human chordoma cell lines. Spine 2010;35(13):1257-64
27. Ostroumov E, Hunter CJ. The role of extracellular factors in human metastatic chordoma cell growth in vitro. Spine 2007;32(26):2957-64
28. DeComas AM, Penfornis P, Harris MR, et al. Derivation and characterization of an extra-axial chordoma cell line (EACH-1) from a scapular tumor. J Bone Joint Surg Am 2010;92(5):1231-40
29. Rinner B, Froehlich EV, Buerger K, et al. Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1. Int J Oncol 2012;40(2):443-51
30. Chugh R, Dunn R, Zalupski MM, et al. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol 2005;23(15):3597-604
31. York JE, Kaczaraj A, Abi-Said D, et al. Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery 1999;44(1):74-9; discussion 79-80
32. Stacchiotti S, Longhi A, Ferraresi V, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol 2012;30(9):914-20
33. Casali PG, Messina A, Stacchiotti S, et al. Imatinib mesylate in chordoma. Cancer 2004;101(9):2086-97
34. Weinberger PM, Yu Z, Kowalski D, et al. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg 2005;131(8):707-11
35. Hof H, Welzel T, Debus J. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie 2006;29(12):572-4
36. Yang C, Schwab JH, Schoenfeld AJ, et al. A novel target for treatment of chordoma: Signal transducers and activators of transcription 3. Mol Cancer Ther 2009;8(9):2597-605
37. Yang C, Hornicek FJ, Wood KB, et al. Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma. Spine 2010;35(18):1668-75
38. Negri T, Casieri P, Miselli F, et al. Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient. Br J Cancer 2007;96(1):180-1